Nebenwirkungen · Filgrastim Hexal
Filgrastim HEXAL 30 MU/0.5 mL solution for injection or infusion in pre-filled syringe Filgrastim HEXAL 48 MU/0.5 mL solution for injection or infusion in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 15
HOS-209653 · Präparat HOS-154345
Hypersensitivity-type reactions including anaphylaxis, rash, urticaria, angioedema, dyspnoea and hypotension occurring on initial or subsequent treatment have been reported in clinical studies and in post marketing experience. Overall, reports were more common after IV administration. In some cases, symptoms have recurred with rechallenge, suggesting a causal relationship. Filgrastim should be permanently discontinued in patients who experience a serious allergic reaction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T12:41:00Z · SHA-256 83b07123404f62aa7b58fc9646c7d49724612fc3405ea7378cdce408567ccc18 · Passage d1c36be01693de8ee21bebcdd59294c4199c267f8cf3e876a3f69323c779ea21 · Zeichen 7582–8059 im Abschnitt